Dashboard
Company has a low Debt to Equity ratio (avg) at 0.01 times
Poor long term growth as Operating profit has grown by an annual rate 7.38% of over the last 5 years
Positive results in Sep 26
Stock is technically in a Bullish range
With ROE of 10.3, it has a Fair valuation with a 2.6 Price to Book Value
High Institutional Holdings at 41.83%
Stock DNA
Pharmaceuticals & Biotechnology
INR 103,795 Cr (Mid Cap)
25.00
40
0.39%
-0.03
10.31%
2.64
Total Returns (Price + Dividend) 
Latest dividend: 7 per share ex-dividend date: Nov-11-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Aurobindo Pharma Ltd. is Rated Hold by MarketsMOJO
Aurobindo Pharma Ltd. is currently rated 'Hold' by MarketsMOJO, a rating that was last updated on 25 May 2026. While this rating adjustment occurred several months ago, the analysis and financial metrics presented here reflect the stock's current position as of 20 November 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read More
Aurobindo Pharma Sees Significant Open Interest Surge Amid Mixed Market Signals
Aurobindo Pharma Ltd. has witnessed a notable 10.57% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a marginal decline in the stock price and subdued volume, the surge in open interest suggests that traders are recalibrating their directional bets amid a complex market backdrop.
Read More
Aurobindo Pharma Sees Sharp Open Interest Surge Amidst Narrow Price Range
Aurobindo Pharma Ltd. has witnessed a notable 13.9% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week high, the stock’s mixed volume and delivery trends suggest cautious optimism among traders navigating the pharmaceuticals sector.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
19-Nov-2026 | Source : BSESubmission of copy of notice published in newspapers.
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
18-Nov-2026 | Source : BSESubmission of Postal Ballot Notice.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
11-Nov-2026 | Source : BSESubmission of Earning Call Transcript for Q2FY27.
Corporate Actions 
No Upcoming Board Meetings
Aurobindo Pharma Ltd. has declared 700% dividend, ex-date: 11 Nov 26
Aurobindo Pharma Ltd. has announced 1:5 stock split, ex-date: 10 Feb 11
Aurobindo Pharma Ltd. has announced 1:1 bonus issue, ex-date: 20 Jul 15
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
11.9897
Held by 44 Schemes (16.31%)
Held by 756 FIIs (17.41%)
Rpr Sons Advisors Private Limited, Mrs.p.suneela Rani (jointly Holding) (33.54%)
Quant Mutual Fund - Quant Arbitrage Fund (4.91%)
5.02%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 12.16% vs 3.35% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 9.06% vs 12.08% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 5.15% vs 9.19% in Sep 2024
Growth in half year ended Sep 2025 is -3.65% vs 30.77% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 6.25% vs 8.96% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 0.04% vs 14.05% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 6.08% vs 9.39% in Mar 2025
YoY Growth in year ended Mar 2026 is 0.54% vs 9.86% in Mar 2025